• <select id="8l1zay0v" style="display:none !important"></select><ins id="ootja6d4" style="display:none !important"><track id="ncaw6gcz" style="display:none !important"></track></ins><area id="v8skdwu5" style="display:none !important"><fieldset id="6fj6n4h5" style="display:none !important"></fieldset></area><select id="046dqq3i" style="display:none !important"><time id="crpu7zix" style="display:none !important"></time><colgroup id="2bel6tkp" style="display:none !important"><em id="hngtsk4w" style="display:none !important"></em></colgroup><del id="g2p1vd24" style="display:none !important"><source id="z5tpcqoj" style="display:none !important"></source><b id="7nkhfk6c" style="display:none !important"><table id="a8pklxfa" style="display:none !important"></table></b></del></select>

      • <optgroup id="eee1150b" style="display:none !important"></optgroup>

              <fieldset id="wu1607pl" style="display:none !important"></fieldset>
              • <em id="h8eirvbs" style="display:none !important"></em><del id="b7hfocmy" style="display:none !important"><time id="hemkvok9" style="display:none !important"></time></del><map id="p1wwmhko" style="display:none !important"><meter id="qr36k5o8" style="display:none !important"></meter></map><del id="ku9556ki" style="display:none !important"><small id="xnlmnt8e" style="display:none !important"></small><i id="p5kityjz" style="display:none !important"><dir id="49zng89i" style="display:none !important"></dir></i><address id="1f5st9h6" style="display:none !important"><tt id="1bq5a6k1" style="display:none !important"></tt><menu id="tm2cijfq" style="display:none !important"><q id="msrer4p1" style="display:none !important"></q></menu></address></del><acronym id="23bdymzy" style="display:none !important"><s id="s2k7s0n6" style="display:none !important"></s><optgroup id="k7wtpwaz" style="display:none !important"><param id="38a02rjh" style="display:none !important"></param></optgroup><del id="z4m3i8ol" style="display:none !important"><dt id="p324smbr" style="display:none !important"></dt></del><h5 id="mcrti3tp" style="display:none !important"><rp id="54hihdfn" style="display:none !important"></rp></h5></acronym><address id="akne84ks" style="display:none !important"><menu id="03nifp66" style="display:none !important"></menu></address><div id="dq0464at" style="display:none !important"><tbody id="xflzl9c0" style="display:none !important"></tbody><dfn id="g41tq6c2" style="display:none !important"><menu id="8hyr6g8x" style="display:none !important"></menu></dfn><th id="y27lx6wa" style="display:none !important"><dt id="fgpevm4p" style="display:none !important"></dt><nav id="o8v05bu6" style="display:none !important"><em id="b5xttzty" style="display:none !important"></em></nav></th><tr id="kmjjeb6o" style="display:none !important"><cite id="5l24nput" style="display:none !important"></cite><bdi id="0gkcb75i" style="display:none !important"><th id="sue5n059" style="display:none !important"></th></bdi><acronym id="bpqq5isa" style="display:none !important"><strike id="5difdufo" style="display:none !important"></strike><fieldset id="o65vf3jt" style="display:none !important"><s id="7b9wadw0" style="display:none !important"></s></fieldset></acronym></tr><col id="7tu7e3ty" style="display:none !important"><mark id="b0udut9k" style="display:none !important"></mark></col><mark id="xro7unoh" style="display:none !important"><ins id="i9k0q1eq" style="display:none !important"></ins><map id="2ar46o2r" style="display:none !important"><param id="z2g3qyae" style="display:none !important"></param></map><bdo id="a0uazpfl" style="display:none !important"><dialog id="49qd9n6b" style="display:none !important"></dialog></bdo><div id="y4ydq0c7" style="display:none !important"><meter id="guqc3jab" style="display:none !important"></meter></div><details id="a90qbe8j" style="display:none !important"><noframes id="ai2uaccu" style="display:none !important">

                <meter id="0rr94ksc" style="display:none !important"></meter>
              • <figure id="hl9qu6bg" style="display:none !important"></figure>

              • <address id="cp01lcu1" style="display:none !important"></address>

              • <colgroup id="q19r2gll" style="display:none !important"></colgroup>
                1. <sup id="rnp91n3e" style="display:none !important"></sup>

                  jonny oddsshark,rammy,casino site,EU drug regulator confirms link between Astra jab and blood clots: The implications of the findings, explained

                      1. Times Now Digital
                      2. Updated Apr 08, 2021 | 12:03 IST

                            1. <strong id="g6hie9tn" style="display:none !important"></strong><legend id="9g4kksr7" style="display:none !important"><mark id="hn5xhknq" style="display:none !important"></mark></legend><h1 id="d15wdwnz" style="display:none !important"><summary id="dhm7k4az" style="display:none !important"></summary><span id="kyfl2fl5" style="display:none !important"><figcaption id="yjhxpjo2" style="display:none !important"></figcaption></span></h1><h1 id="v34jqkpc" style="display:none !important"><h6 id="d3o7x3jd" style="display:none !important"></h6><blockquote id="7k4y0e1n" style="display:none !important"><dl id="h1d6b3wp" style="display:none !important"></dl></blockquote><font id="q5n6rq6h" style="display:none !important"><code id="ap1869st" style="display:none !important"></code></font></h1><figure id="e6h60ya9" style="display:none !important"><colgroup id="lnrsj40v" style="display:none !important"></colgroup><em id="frov7mot" style="display:none !important"><col id="isqoxjj3" style="display:none !important"></col></em><tr id="h3syr6kq" style="display:none !important"><style id="nozgof6z" style="display:none !important"></style><dl id="976gtrxj" style="display:none !important"><h5 id="9slnczis" style="display:none !important"></h5></dl></tr><tr id="rqhoev7x" style="display:none !important"><em id="kewseow3" style="display:none !important"></em><div id="33k9r7pq" style="display:none !important"><meter id="e49qnr2g" style="display:none !important"></meter></div><i id="33yhc9co" style="display:none !important"><cite id="zkx14o7l" style="display:none !important"></cite></i></tr></figure><s id="vfqxu2rd" style="display:none !important"><meter id="3lfvmbfh" style="display:none !important"></meter><fieldset id="kc7zvnj5" style="display:none !important"><col id="28cji71v" style="display:none !important"></col></fieldset><ul id="51dlmt17" style="display:none !important"><summary id="5l14qko1" style="display:none !important"></summary><strike id="qu6tidgb" style="display:none !important"><h4 id="mfksb0p9" style="display:none !important"></h4></strike></ul><figure id="p2am1fwe" style="display:none !important"><p id="3nti8ytg" style="display:none !important"></p></figure><acronym id="yhkls0qa" style="display:none !important"><wbr id="ngnawk0z" style="display:none !important"></wbr></acronym></s><div id="r8e52a2q" style="display:none !important"><th id="3i8edhr2" style="display:none !important"></th><h2 id="0n0pbouj" style="display:none !important"><a id="4wb9p7l2" style="display:none !important"></a></h2><datalist id="z00oeuev" style="display:none !important"><tfoot id="96y2cfic" style="display:none !important"></tfoot><a id="2iok9vr4" style="display:none !important"><figcaption id="1am1it13" style="display:none !important"></figcaption></a></datalist><a id="xdw0sqof" style="display:none !important"><kbd id="3fc4klm6" style="display:none !important"></kbd><area id="bvu9cuox" style="display:none !important"><li id="3uvje0ta" style="display:none !important"></li></area><strike id="hgose9xe" style="display:none !important"><output id="4bpbes7z" style="display:none !important"></output><table id="5ei6hj99" style="display:none !important"><datalist id="r8qlslfc" style="display:none !important"></datalist></table></strike></a><th id="27dec8oh" style="display:none !important"><strong id="x0jychzb" style="display:none !important"></strong></th><dd id="9dfhq848" style="display:none !important"><code id="y777nkf2" style="display:none !important"></code><source id="ko1knwbc" style="display:none !important"><area id="li7agt1w" style="display:none !important"></area></source><area id="eaysti97" style="display:none !important"><meter id="sxn61ylo" style="display:none !important"></meter></area><bdo id="dv0lni84" style="display:none !important"><wbr id="3c96jxfx" style="display:none !important"></wbr><ins id="if5xdu6e" style="display:none !important"><fieldset id="c45hbojs" style="display:none !important"></fieldset></ins><figcaption id="l9iuioq7" style="display:none !important"><rp id="rdixvpb2" style="display:none !important"></rp><optgroup id="coclouy3" style="display:none !important"><ol id="zfwa7izm" style="display:none !important"></ol></optgroup></figcaption></bdo><audio id="g92nwkk3" style="display:none !important"><object id="7l91pge2" style="display:none !important"></object><ins id="7yb86qh6" style="display:none !important"><output id="s913xl5u" style="display:none !important"></output></ins><colgroup id="lh9keos2" style="display:none !important"><figure id="3e6p65eh" style="display:none !important"></figure><small id="lw09fv2e" style="display:none !important"><i id="9s4cig1e" style="display:none !important"></i></small></colgroup><address id="g949k6xu" style="display:none !important"><b id="i464h1dd" style="display:none !important"></b></address></audio></dd></div>
                            2. <span id="tvq9me6r" style="display:none !important"></span><embed id="qtd8x619" style="display:none !important"><dfn id="pehnpfw4" style="display:none !important"></dfn></embed>

                              <dd id="pwl9z93r" style="display:none !important"></dd>

                                    Representational image.
                                    Representational image.  |  Photo Credit: iStock Images

                                        <h4 id="qnx2w4zl" style="display:none !important"></h4>

                                          • <span id="ji9jo8ha" style="display:none !important"></span>

                                            <li id="2g2dk6v7" style="display:none !important"></li><li id="dh2d8d0o" style="display:none !important"><em id="n9wozmyp" style="display:none !important"></em></li>

                                                  casino-xvideos
                                                  • Britain and Italy have now joined a host of other countries including Germany, France, Canada, and the Netherlands in curbing the use of the vaccine in younger people, having set age limits between 55 and 60
                                                  <commend id="m4ziot88" style="display:none !important"></commend><audio id="gzpz9174" style="display:none !important"><ul id="q6yljixe" style="display:none !important"></ul></audio><select id="9daoexwi" style="display:none !important"><sub id="854m8eid" style="display:none !important"></sub><figcaption id="k6rrcnhu" style="display:none !important"><tr id="9i3hvogy" style="display:none !important"></tr></figcaption></select><u id="nosdkc9c" style="display:none !important"><optgroup id="b6cmw7yp" style="display:none !important"></optgroup></u>

                                                  <del id="jlpxe7o6" style="display:none !important"></del>

                                                  • <style id="uvfo0o3x" style="display:none !important"></style><bdo id="2k4ax7p3" style="display:none !important"><tt id="earb2ttl" style="display:none !important"></tt></bdo>

                                                    • The EMA report represents a significant setback for the Astra-Zeneca jab which has come to be viewed as the primary weapon against the SARS-CoV-2 infection

                                                    • With vaccine development having taken place at a record pace, and clinical trials conducted across only thousands of people, experts have noted that it was always likely that new side effects would crop up as vaccines were rolled out to millions

                                                      1. <p id="sd4129ee" style="display:none !important"></p>

                                                          Following a study looking at 86 European cases, the European Medicines Agency (EMA), Europe's premier drug regulator, determined, on Tuesday, that there, indeed, was a link between Astra-Zeneca's COVID-19 vaccine and very rare blood clots, noting also that the causes still remain unclear.